Zydus launches Ujvira (Trastuzumab Emtansine), a ... - Pipelinereview
WEBMay 24, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
First Wave BioPharma Announces Completion of Business
WEBMar 15, 2024 · Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease. James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer
Nektar and Bristol Myers Squibb Announce Update on Clinical …
WEBApr 15, 2022 · PRINCETON, NJ and SAN FRANCISCO, CA, USA I April 14, 2022 INektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement …
WEBMar 13, 2024 · Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations.
Evergreen Theragnostics Completes $26M Capital Raise
WEBApr 16, 2024 · SPRINGFIELD, NJ, USA I April 16, 2024 I Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.The financing advances Evergreen’s novel discovery pipeline into clinical trials, supports commercialization of its ...
Fresenius Accelerates Momentum in its (Bio)Pharma
WEBApr 16, 2024 · Tyenne ® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous formulation approved by the FDA.. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients. Excellent performance of the (Bio)Pharma business in 2024 so far, also driven by Tyenne ...
Seneca Therapeutics, Inc. Presents Promising New Preclinical Data ...
WEBApr 11, 2022 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Silence Therapeutics Announces Positive Topline 36-Week Data …
WEBMar 13, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
PhoreMost enters multi-target collaboration with targeted protein ...
WEBOct 30, 2022 · PhoreMost to deploy its SITESEEKER® Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets. CAMBRIDGE, UK I October 28, 2022 I PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-target collaboration with Arvinas, an industry leader in ...
Skip to content